

ATVB IN FOCUS:

Research Highlights From the Blood and Bone Marrow Webinar Series

Series Editor: Kellie R. Machlus

Computationally Driven Discovery in Coagulation

Kathryn G. Link, Michael T. Stobb, Dougald M. Monroe, Aaron L. Fogelson, Keith B. Neeves, Suzanne S. Sindi, Karin Leiderman^{1D}

ABSTRACT: Bleeding frequency and severity within clinical categories of hemophilia A are highly variable and the origin of this variation is unknown. Solving this mystery in coagulation requires the generation and analysis of large data sets comprised of experimental outputs or patient samples, both of which are subject to limited availability. In this review, we describe how a computationally driven approach bypasses such limitations by generating large synthetic patient data sets. These data sets were created with a mechanistic mathematical model, by varying the model inputs, clotting factor, and inhibitor concentrations, within normal physiological ranges. Specific mathematical metrics were chosen from the model output, used as a surrogate measure for bleeding severity, and statistically analyzed for further exploration and hypothesis generation. We highlight results from our recent study that employed this computationally driven approach to identify FV (factor V) as a key modifier of thrombin generation in mild to moderate hemophilia A, which was confirmed with complementary experimental assays. The mathematical model was used further to propose a potential mechanism for these observations whereby thrombin generation is rescued in FVIII-deficient plasma due to reduced substrate competition between FV and FVIII for FXa (activated factor X).

GRAPHIC ABSTRACT: A [graphic abstract](#) is available for this article.

Key Words: algorithms ■ hemophilia A ■ machine learning ■ plasma ■ thrombin

This review highlights our recent study in which we used computational modeling to discover a potential modifier of thrombin generation in mild to moderate hemophilia A.¹ We were motivated by the variation in bleeding frequency and severity within clinical categories—severe, moderate, mild—of hemophilia A,^{2,3} characterized by coagulation FVIII (factor VIII) levels of <1%, 1% to 5%, and 5% to 20%, respectively. Although the bleeding severity in the majority of patients correlates with their factor levels, up to 10% of patients in the severe category have a bleeding phenotype that would be classified clinically as mild.^{4,5} The underlying mechanism(s) of these observations are unknown. This prompts the question: in the case of severe quantitative defects with mild bleeding, what is compensating for the deficient clotting protein? If we can answer that question, we may identify variable(s) that can be adjusted or

Please see www.ahajournals.org/atvb/atvb-focus for all articles published in this series.

manipulated to improve outcomes for patients with high-frequency bleeding and, more generally, help predict bleeding patterns early in life, before serious bleeding begins. However, numerous variables could potentially be at play either working alone, additively, antagonistically, or synergistically. These variables could be biological, biochemical, or biophysical in nature. Measuring all possible variables in a clinical environment or testing how single variables affect the clotting response under flow, one at a time, would be time consuming and expensive, and in some cases, not possible. Our goal was to exploit the efficiency of a computationally driven approach to search for clues to solve this scientific mystery.

Correspondence to: Karin Leiderman, Colorado School of Mines, Applied Mathematics and Statistics, 1500 Illinois St, Chauvenet Hall 141, Golden, CO 80401. Email kleiderman@mines.edu

For Sources of Funding and Disclosures, see page 85.

© 2020 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at www.ahajournals.org/journal/atvb

Nonstandard Abbreviations and Acronyms

F	factor
TF	tissue factor

Data-Driven Versus Computationally Driven Approaches to Discovery in Coagulation

Discovering these clues, particularly if multiple factors are involved, requires the generation and analysis of large data sets comprised of experimental outputs or patient samples. One approach to this problem is to simply look for patterns in such data sets with statistical or machine learning algorithms, an approach known as data-driven. In this case, algorithms are trained on existing data sets to learn features that are associated with well-defined outcomes. These approaches typically improve with exposure to more and more data and with good data sets and well-defined inputs and outputs; these approaches can yield useful predictive tools. For example, machine learning was used to inform dosing strategies for warfarin,^{6–8} which is known to have a wide interindividual variability in dose requirement,⁹ incorporating dozens of input characteristics for thousands of patients. Another example of this approach is from Chatterjee et al,¹⁰ in which a data set was generated in vitro specifically to train a machine learning algorithm to learn platelet calcium responses, the ultimate goal being prediction of responses due to any combination of agonists beyond the training data. This method was extended to handle additional agonists to generate a human platelet calcium calculator¹¹ and used to predict platelet activation states within a large multiscale mathematical model of platelet deposition under flow.¹² Machine learning algorithms can identify patterns and serve as powerful prediction tools, but because of their nonmechanistic nature, they may not be able to determine the mechanism(s) underlying those patterns.

To address our question using a data-driven approach, we first needed to determine if generating an ideal experimental data set was even feasible. An ideal data set would involve systematic variation of clotting factor and inhibitor concentrations and subsequent monitoring of thrombin generation and thrombus formation under flow, for each variation. This can quickly require a very large number of complicated experiments, for example, choosing only 5 clotting factors to vary could result in over 2000 different possible combinations, plus technical replicates. Furthermore, unless a synthetic plasma is used for the experiments, modulating the levels of individual clotting factors in whole blood is challenging. Performing a handful of these experiments is certainly doable but generating the entire desired data set is not. This roadblock, combined with our goal to understand

Highlights

- Computational approaches complement experimental ones and enable discovery in coagulation.
- Enormous synthetic data sets, created with computational models, can be used for focused and efficient searches for modifiers of coagulation.
- Iterating between mathematical predictions, experimental validation, and mathematical exploration of mechanism allowed for identification of FV (factor V) as a modifier of thrombin generation in mild to moderate hemophilia A.

the mechanism(s) underlying the observed variability in bleeding severity, led us to take a different approach that we call computationally driven. We illustrate our computational driven framework in Figure 1.

What if instead of generating a large experimental data set, we use a mathematical model to generate a large computational data set? In such mathematical experiments, we can easily and systematically vary all of the clotting factor and inhibitor concentrations within a specified range. For each set of variations, we then run the model to produce a computational prediction of thrombin generation and clot formation under flow. This process allowed us to, in essence, create a mathematical depiction of thrombin generation in hundreds of thousands of individuals with moderate to mild hemophilia A, or in other words, create synthetic patient data. Generation of this type of data set is possible because of computational efficiency since one of the simulations takes only seconds to complete. We can generate a massive amount of data that can subsequently be statistically analyzed to extract and identify complex interactions between multiple clotting factors or inhibitors, as we illustrate in Figure 2. Moreover, with a mechanistic mathematical model, as further described below, we have access to the time-varying concentrations of every coagulation reactant and reaction intermediate, which enables us to search for biochemical mechanisms underlying any patterns found in the data. This means that, with our model, in addition to monitoring the changes that occur in the output (thrombin generation), we can determine how those changes occur.

To statistically analyze the synthetic patient data, we first need a mathematical metric to serve as a surrogate for bleeding severity and then need to study how that metric is affected by manipulations of model inputs. We chose thrombin generation as our surrogate metric of bleeding severity and clotting factor and inhibitor levels that are input into the mathematical model as potential biomarkers. Our choice of metric is suitable since thrombin generation is decreased in hemophilias A and B; deficiency in clotting factors VIII or IX leads to decreased thrombin generation since they comprise the tenase




Figure 1. Computationally driven approach for discovery in coagulation.

A mechanistic mathematical model is used to create large synthetic patient samples which are then analyzed to reveal modifiers, propose mechanisms, and generate hypotheses for experimental validation.

complex, which is necessary for the propagation phase of coagulation and subsequent robust thrombin generation. We chose clotting factors and inhibitors as inputs since they are commonly measured and because, interestingly, their normal ranges are accepted as around 50% to 150% of the mean values of the healthy population.^{13,14} Because of this known variation, we hypothesized there could be clues hidden within the plasma composition and that there may be synergistic or antagonistic behavior between proteins at levels still considered normal. To test this hypothesis, we asked the following question: how do clotting factor and inhibitor levels alter thrombin generation during flow-mediated coagulation when factor VIII is deficient? Investigating this question requires the use of a mechanistic dynamic model that describes flow-mediated coagulation. We next describe what we mean by dynamic models and briefly review some dynamic models of coagulation.

Dynamic Models and Coagulation Thresholds

A dynamic model of coagulation is a mathematical representation of a network of biochemical reactions that yields time-varying concentrations of coagulation proteins. A mechanistic dynamic model of coagulation is one that is based on explicit consideration of the reactions

that yield observed thrombin generation data; an example of a nonmechanistic model of coagulation is a descriptive model that provides a quantitative summary of observed data, such as using linear regression to fit a line to data. The Mann laboratory developed one of the first dynamic models of the extrinsic blood coagulation system. That model displayed a nonlinear, threshold-like dependence of thrombin generation on concentrations of TF (tissue factor) bound to FVIIa, tissue factor pathway inhibitor, and antithrombin,^{15,16} which agreed well with previous observations made in the authors' experimental studies using synthetic plasma.¹⁷ In relation to our work described below, the Mann model was also used in a combined experimental and computational approach to investigate variation in thrombin generation in mild to moderate hemophilia A as a result of changing other variables in the model.¹⁸ The authors simulated thrombin generation at various concentrations of FVIII with other factor levels set to either all high-normal (150% of mean values) or all low-normal levels (50% of mean values). Interestingly, their model showed that if all factor levels are at high-normal levels when FVIII is low, that the thrombin generation can be slightly enhanced. This model has been used extensively to investigate sensitivity to normal variations of clotting factors in healthy individuals,¹⁹ to assess risk of disease,²⁰ and to investigate mechanisms underlying




Figure 2. A mathematical model of coagulation under flow identifies FV (factor V) as a modifier of thrombin generation in hemophilia A.

FV is a modifier of thrombin generation in a mathematical model of flow-mediated coagulation. **A**, Thrombin concentration time series generated by uniformly and independently varying plasma protein levels including inhibitors tissue pathway inhibitor (TFPI) and antithrombin (AT) $\pm 50\%$ from normal (110 000 total simulations); mean (solid black line), boundaries that encompass 50% (pink), 90% of the data (orange), and the maximum/minimum of the computed solutions (gray-dashed); blue line drawn at 1 nM. **B**, First (blue) and total (orange) order Sobol indices are plotted as mean $\pm$ SD computed with 5000 bootstrap samples of the original 110 000 simulations. **C**, Plasma protein levels distributions shown as box-and-whisker plots (mean in red, whiskers drawn at $3\times$ the interquartile range), conditioned on achieving >1 nM of total thrombin by 40 min. **D**, Calibrated automated thrombography. FVIII-deficient ($<10\%$) plasma treated with vehicle control, 50 $\mu\text{g/mL}$ exogenous prothrombin, 100 $\mu\text{g/mL}$ anti-FV, and exogenous prothrombin and anti-FV. Assay conducted with 5 pM TF (tissue factor) and phospholipids. **E**, Flow assays with whole blood from FVIII-deficient individuals. **A**, Representative images of DiQC6 labeled platelets and leukocytes and Alexa Fluor 555 labeled fibrin(ogen) on collagen-TF surfaces at 100 per second after 25 min for vehicle control, 50 $\mu\text{g/mL}$ exogenous prothrombin, 100 $\mu\text{g/mL}$ anti-FV, and exogenous prothrombin and anti-FV. Scale bar=50 μm . CS indicates condition for samples; and VAT, variance analysis time.

complications of trauma and coagulopathies,^{21,22} but it does not explicitly consider lipid surfaces, either phospholipid vesicles or activated platelet surfaces, known to regulate coagulation.^{23–25} Collectively, these studies suggest that the type of surface, that is, lipid vesicle versus platelet surface, may be important in differentiating and understanding coagulation thresholds.²⁶ Additionally,

biophysical effects on coagulation such as flow and diffusion likely contribute to how the thresholds manifest in vivo, but that cannot be studied with static models. We refer the reader interested in models of static coagulation to other reviews.^{27–31}

Models incorporating the dynamic interplay between flow, surface, and coagulation allow for investigations

considering transport effects. Kuharsky and Fogelson³² developed a model (denoted as KF model) to simulate thrombin generation at the site of a small vascular injury under flow. The model accounts for platelets, platelet deposition, and surface-mediated coagulation reactions, all under flow. Transport of each protein and platelet species to and from the reaction zone by flow and diffusion is described using mass transfer coefficients.³³ The reaction zone is a region located just above a small patch of exposed subendothelium; its height is defined by how high a protein molecule can be above the injury and still diffuse to the injury before being carried away by the flow. The authors proposed an inhibitory, anticoagulant role for the adherent platelets, namely that they physically inhibit the enzyme complexes embedded in the injury patch. This notion of paving over the injury was later confirmed experimentally.³⁴ The KF model was later extended to include endothelial cell reactions³⁵ and the FXI pathway.³⁶ Results from these models aided in proposing testable hypotheses including thrombin generation dependence on a surface tissue factor threshold under flow^{32,35} (later experimentally validated at venous and arterial shear rates³⁷); the effects of platelet count on thrombin generation under flow in hemophilia C³⁶; and the effects of FXIa and TF in postintravenous immunoglobulin treatment of thrombotic events.³⁸ There are a variety of other models of clotting under flow, using different mathematical and computational techniques, including some spatial models that account for each individual red blood cell and platelet. Here, we base our studies on the extended version of the KF model but refer the reader to other reviews devoted to this topic.^{39–47}

Quantifying Uncertainty in Computational Models

The extended KF model, as well as other models described above, rely on numerous assumptions regarding the biochemical reaction networks, kinetic rate constants, and the experimental assays used for model calibration. The inherent uncertainty in these assumptions raises an issue of the value of kinetic modeling of thrombin generation for prediction and proposal of testable hypothesis.^{48,49} A main point of contention involves thrombin generation simulated with different existing mathematical models giving contrasting results, even when using the same initial concentrations of plasma proteins.⁴⁸ Counter arguments in favor of mathematical modeling stress that for a model to be truly predictive and accurately simulate coagulation reactions and perturbations; it must be carefully validated with the experiments that it simulates, and any additional sources of uncertainty and variability should be quantified. Statistical methods attempt to examine the extent to which model outputs depend on model inputs. Specifically, sensitivity analysis and uncertainty quantification

methods seek to assess how the uncertainty in a model input (such as a kinetic rate or factor level) propagates through the model to produce variations in a model output (such as the level of thrombin at a particular time). Many uncertainty quantification approaches exist and, depending on the question under investigation, they may be employed to identify plausible ranges of model inputs from observations of model outputs or to investigate the variability, uncertainty, and goodness of a particular computational model itself.

Sensitivity analysis techniques have been used to study static and flow-mediated models of coagulation.^{15,19,50–52} Danforth et al⁵⁰ performed a local sensitivity analysis of the Mann model¹⁵ to investigate the sensitivity of thrombin generation as a function of its reaction rates, as well as to investigate the sensitivity of thrombin production to initial coagulation protein concentrations¹⁹ alone or through their pairwise changes/interactions. A similar analysis was conducted by Naidu and Anand⁵¹ on the model of Anand et al.⁵³ In Link et al,⁵⁴ a tailored sensitivity analysis approach was developed to analyze the effects of variability within the model of Fogelson et al.³⁶ In that approach, concentrations of coagulation proteins, kinetic rate constants, and biophysical and platelet specific parameters were varied. Robust thrombin production was seen for variations of plasma proteins within the physiological range, and wider variations in thrombin generation occurred with variation in individual kinetic rate constants.

Identifying FV as a Modifier of Thrombin Generation in Hemophilia A Using a Computationally Driven Approach

Using our mathematical model³⁶ and computationally driven approach, we generated an enormous amount of synthetic patient data and used it to identify FV as a modifier of thrombin generation in mild to moderate hemophilia A. All simulations used to generate the data set considered a low TF density of 5 fmol/cm² and a low shear rate of 100 s⁻¹. Motivated by our previous studies,^{32,35,38} we first did an initial screening and determined a range of critical TF levels where thrombin sharply transitioned between an attenuated response with thrombin peaking at a concentration below 1 nmol/L and an amplified thrombin response in which the thrombin concentration reached at least 1 nmol/L by 40 minutes; the TF range is 4.63 to 7.78 fmol/cm² for FVIII-deficient plasma. Since individuals with FVIII deficiencies are known to bleed in regions of the body with low TF levels,^{55–57} we chose a single TF level, 5 fmol/cm², near the low end of our computationally determined critical TF range.

Our synthetic patient data set exhibited large variance in thrombin generation due to changes in clotting factor and inhibitor levels, see Figure 2A. To determine

which clotting factor and inhibitor levels were the most important for enhancing thrombin generation within our synthetic data set, we used Sobol sensitivity analysis⁵⁸ to determine the fraction of the observed variance in thrombin generation that was attributable to each factor or inhibitor level, see Figure 2B. We found that FV and prothrombin (FII) contributed the most to the variance, with their interaction explaining nearly 20% of it. We then looked more directly at the $\approx 5\%$ of simulations that produced an amplified thrombin response (see above) in FVIII-deficient plasma. We examined the plasma clotting factor and inhibitor levels that produced the amplified response and observed that the distributions of these levels were highly skewed for 2 factors: FV and prothrombin. All simulations with an amplified response had plasma FV level of $<75\%$ of its mean population level and most had a prothrombin level above 125% of its mean population level (shown in Figure 2C). These results indicated that, within our mathematical model, low-normal FV levels and high-normal prothrombin levels enhanced thrombin generation in FVIII-deficient plasma and thus FV and FII became leading candidates as potential modifiers of thrombin generation.

Our mathematically identified candidates, FV and prothrombin, were then confirmed as modifiers by calibrated automated thrombography and microfluidic flow assays⁵⁹ on collagen-tissue factor surfaces at a shear rate of 100 s^{-1} utilizing both FVIII-inhibited plasma and whole blood from FVIII-deficient individuals. Using mixtures of FV and prothrombin-depleted plasmas, purified FV and prothrombin, and an anti-FVIII function-blocking antibody yielding FVIII activity of $<1\%$, we generated four cases of variations in FII and FV plasma levels. Results were consistent with the mathematical model, showing that low-normal FV (43%) increased the peak thrombin concentration and endogenous thrombin potential and that both of these measures were further enhanced with high prothrombin (136%). Similar trends were seen with FVIII-deficient plasma from individuals using the same treatments as in the microfluidic flow assay experiments, see Figure 2D. Whole blood microfluidic assays were performed using both synthetic plasma and blood from individuals with moderate and mild FVIII deficiencies. There was a significant increase in both the rate and maximum accumulation of fibrin(ogen) with partial inhibition of FV via the anti-FV antibody, and an even greater response occurred with the addition of prothrombin, see Figure 2E.

What could be the basis of this enhanced response? Because our model is mechanistic, we are able to probe it further to determine which reactions in the coagulation system become more effective on the path to thrombin generation when FV is in the low-normal range. Doing so allowed us to recognize that in the model the mechanism for enhanced thrombin production is decreased substrate competition of platelet-bound FV with platelet-bound

FVIII to bind to and be activated by platelet-bound FXa (activated factor X). In our simulations, FXa is the dominant activator of FV and FVIII before significant amounts of thrombin have been produced; therefore, FV and FVIII compete to form their respective substrate-enzyme complexes before their cleavage to FVa (activated factor V) and FVIIIa (activated factor FVIII). Model results showed higher concentrations of substrate-enzyme complexes (FVIII with FXa) for low-normal FV cases, indicating that lowering FV levels increases activation of FVIII by FXa. Further evidence in support of this mechanism is that decreasing the kinetic rate constant for the association of platelet-bound FV and FXa by 50% led to 30-fold higher thrombin concentrations (with normal FV levels) by 40 minutes. These results support the notion that reducing substrate competition between FV and FVIII for FXa is the mechanism (in the model) by which thrombin generation is rescued in FVIII-deficient plasma.

The model results and explorations of mechanism described above were performed under the assumption of severe hemophilia whereby extremely low levels of FVIII were used in the model (1% of normal or about 0.01 nmol/L) and for normal and low-normal levels of FV. Additional simulations showed that a further decrease in FV levels (down to about 10%) enhanced thrombin generation and further increase in FV levels (up to 200%) inhibits thrombin generation. Below an FV level of 10%, there was insufficient FV and FVIII to support significant thrombin generation (see Figure S2 in previous article¹). Additionally, we observed variations in thrombin generation when decreasing FV levels from normal to low-normal levels for varying categories of hemophilia A, by using FVIII levels at 1, 3, 5, and 8% (see Figure S6 in our previous article¹). For example, with FVIII at 8%, there was significant thrombin formed by 40 minutes when FV was at normal levels. But when FV was decreased to low-normal levels, there was enhanced thrombin generation as shown by a significant decrease in the time it took the system to achieve that thrombin concentration. These results are in line with a recent study by Shao et al⁶⁰ where peak thrombin concentration in calibrated automated thrombography was decreased when FV was titrated back into blood from individuals with combined FV/FVIII deficiencies.

CONCLUSIONS

In conclusion, computational modeling enables the creation of enormous synthetic patient data sets. These data sets are complementary to clinical or experimentally derived data sets in that they can be screened for specific metrics and statistically analyzed to direct small numbers of difficult experiments or identify biomarkers. As evidenced by our work described in this article, combining computationally driven and experimental approaches enhances the potential to discover modifiers

of coagulation. Further exploration with mechanistic dynamic models can provide focused analysis and predictions of any underlying biochemical mechanisms that lead to patterns in the synthetic data sets. Certainly, computational approaches have their limitations; the models should be simple enough to be truly computationally efficient to run but complex enough to include the relevant biochemistry and biophysics. That said, we think that computational approaches can help steer experimental approaches in directions that otherwise may not have been considered; even if a computational model fails to include one's favorite protein or reaction, they may still provide novel intuition about other proteins and interactions in coagulation, and can also usually be easily modified to consider more species or reactions. With advancements in computational power and technology, we think this is an exciting time to explore computational techniques for further discovery in coagulation.

ARTICLE INFORMATION

Received August 14, 2020; accepted September 30, 2020.

Affiliations

Department of Mathematics, University of California Davis (K.G.L.). Department of Mathematics and Computer Science, Coe College, Cedar Rapids, IA (M.T.S.). Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill (D.M.M.). Departments of Mathematics and Biomedical Engineering, University of Utah, Salt Lake City (A.L.F.). Departments of Bioengineering and Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, Hemophilia and Thrombosis Center, University of Colorado, Denver (K.B.N.). Department of Applied Mathematics, University of California, Merced (S.S.S.). Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden (K.L.).

Sources of Funding

This work was supported in part by the National Institutes of Health (R01HL120728, R01HL151984), the National Science Foundation (CBET-1351672, DMS-1848221), and the Army Research Office (ARO-12369656).

Disclosures

None.

REFERENCES

- Link KG, Stobb MT, Sorrells MG, Bortot M, Ruegg K, Manco-Johnson MJ, Di Paola JA, Sindi SS, Fogelson AL, Leiderman K, et al. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A. *J Thromb Haemost*. 2020;18:306–317. doi: 10.1111/jth.14653
- Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. *J Thromb Haemost*. 2014;12:1935–1939. doi: 10.1111/jth.12672
- Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The orthopaedic outcome study group. *J Intern Med*. 1994;236:391–399. doi: 10.1111/j.1365-2796.1994.tb00815.x
- Aledort LM. Why thrombin generation? From bench to bedside. *Pathophysiol Haemost Thromb*. 2003;33:2–3. doi: 10.1159/000071635
- Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. *Acta Orthop Scand Suppl*. 1965;36(suppl 77):3–132. doi: 10.3109/ort.1965.36.suppl-77.01
- International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*. 2009;360:753–764. doi: 10.1056/NEJMoa0809329
- Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. *Bioinformatics*. 2011;27:1384–1389. doi: 10.1093/bioinformatics/btr159
- Liu R, Li X, Zhang W, Zhou HH. Comparison of nine statistical model based warfarin pharmacogenetic dosing algorithms using the racially diverse International warfarin pharmacogenetic consortium cohort database. *PLoS One*. 2015;10:e0135784. doi: 10.1371/journal.pone.0135784
- Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med*. 1994;121:676–683. doi: 10.7326/0003-4819-121-9-199411010-00009
- Chatterjee MS, Purvis JE, Brass LF, Diamond SL. Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. *Nat Biotechnol*. 2010;28:727–732. doi: 10.1038/nbt.1642
- Lee MY, Diamond SL. A human platelet calcium calculator trained by pairwise agonist scanning. *PLoS Comput Biol*. 2015;11:e1004118. doi: 10.1371/journal.pcbi.1004118
- Flamm MH, Colace TV, Chatterjee MS, Jing H, Zhou S, Jaeger D, Brass LF, Sinno T, Diamond SL. Multiscale prediction of patient-specific platelet function under flow. *Blood*. 2012;120:190–198. doi: 10.1182/blood-2011-10-388140
- Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. *Blood*. 1992;80:1998–2005.
- Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. *Blood*. 1999;94:2169–2178.
- Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. *J Biol Chem*. 2002;277:18322–18333. doi: 10.1074/jbc.M201173200
- Mann KG, Brummel K, Butenas S. What is all that thrombin for? *J Thromb Haemost*. 2003;1:1504–1514. doi: 10.1046/j.1538-7836.2003.00298.x
- van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, anti-thrombin-III, and heparin cofactor-II. *J Biol Chem*. 1997;272:4367–4377.
- Brummel-Ziedins KE, Orfeo T, Rosendaal FR, Undas A, Rivard GE, Butenas S, Mann KG. Empirical and theoretical phenotypic discrimination. *J Thromb Haemost*. 2009;7(suppl 1):181–186.
- Danforth CM, Orfeo T, Everse SJ, Mann KG, Brummel-Ziedins KE. Defining the boundaries of normal thrombin generation: investigations into hemostasis. *PLoS One*. 2012;7:e30385. doi: 10.1371/journal.pone.0030385
- Brummel-Ziedins K. Models for thrombin generation and risk of disease. *J Thromb Haemost*. 2013;11(suppl 1):212–223. doi: 10.1111/jth.12256
- Mitrophanov AY, Rosendaal FR, Reifman J. Computational analysis of inter-subject variability and thrombin generation in dilutional coagulopathy. *Transfusion*. 2012;52:2475–2486. doi: 10.1111/j.1537-2995.2012.03610.x
- Mitrophanov AY, Rosendaal FR, Reifman J. Computational analysis of the effects of reduced temperature on thrombin generation: the contributions of hypothermia to coagulopathy. *Anesth Analg*. 2013;117:565–574. doi: 10.1213/ANE.0b013e31829c3b22
- Hoffman M, Monroe DM III. A cell-based model of hemostasis. *Thromb Haemost*. 2001;85:958–965.
- Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. *Hematol Oncol Clin North Am*. 2007;21:1–11. doi: 10.1016/j.hoc.2006.11.004
- Hoffman MM, Monroe DM. Rethinking the coagulation cascade. *Curr Hematol Rep*. 2005;4:391–396.
- Bungay SD, Gentry PA, Gentry RD. A mathematical model of lipid-mediated thrombin generation. *Math Med Biol*. 2003;20:105–129. doi: 10.1093/imammb/20.1.105
- Diamond SL. Systems biology of coagulation. *J Thromb Haemost*. 2013;11(suppl 1):224–232. doi: 10.1111/jth.12220
- Brummel-Ziedins KE, Everse SJ, Mann KG, Orfeo T. Modeling thrombin generation: plasma composition based approach. *J Thromb Thrombolysis*. 2014;37:32–44. doi: 10.1007/s11239-013-1006-9
- Brummel-Ziedins KE. Developing individualized coagulation profiling of disease risk: thrombin generation dynamic models of the pro and anticoagulant balance. *Thromb Res*. 2014;133 (suppl 1):S9–S11. doi: 10.1016/j.thromres.2014.03.004
- Panteleev MA, Sveshnikova AN, Belyaev AV, Nechipurenko DY, Gudich I, Obyedny SI, Dovlatova N, Fox SC, Holmuhamedov EL. Systems biology and systems pharmacology of thrombosis. *Math Model Nat Phenom*. 2014;9:4–16.

31. Shibeko AM, Panteleev MA. Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics. *Brief Bioinform.* 2016;17:429–439. doi: 10.1093/bib/bbv040
32. Kuharsky AL, Fogelson AL. Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. *Biophys J.* 2001;80:1050–1074. doi: 10.1016/S0006-3495(01)76085-7
33. Rana K, Neeves KB. Blood flow and mass transfer regulation of coagulation. *Blood Rev.* 2016;30:357–368. doi: 10.1016/j.blre.2016.04.004
34. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: *in vitro* clots are impermeable to factor Xa. *Blood.* 2004;104:123–127. doi: 10.1182/blood-2003-12-4352
35. Fogelson AL, Tania N. Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. *Pathophysiol Haemost Thromb.* 2005;34:91–108. doi: 10.1159/000089930
36. Fogelson AL, Hussain YH, Leiderman K. Blood clot formation under flow: the importance of factor XI depends strongly on platelet count. *Biophys J.* 2012;102:10–18. doi: 10.1016/j.bpj.2011.10.048
37. Okorie UM, Denney WS, Chatterjee MS, Neeves KB, Diamond SL. Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow. *Blood.* 2008;111:3507–3513. doi: 10.1182/blood-2007-08-106229
38. Leiderman K, Chang WC, Ovanosov M, Fogelson AL. Synergy between tissue factor and exogenous factor XIa in initiating coagulation. *Arterioscler Thromb Vasc Biol.* 2016;36:2334–2345. doi: 10.1161/ATVBAHA.116.308186
39. Wang W, King MR. Multiscale modeling of platelet adhesion and thrombus growth. *Ann Biomed Eng.* 2012;40:2345–2354. doi: 10.1007/s10439-012-0558-8
40. Fogelson AL, Neeves KB. Fluid mechanics of blood clot formation. *Annu Rev Fluid Mech.* 2015;47:377–403. doi: 10.1146/annurev-fluid-010814-014513
41. Hosseinzadegan H, Tafti DK. Modeling thrombus formation and growth. *Bio-technol Bioeng.* 2017;114:2154–2172. doi: 10.1002/bit.26343
42. Flamm MH, Diamond SL. Multiscale systems biology and physics of thrombosis under flow. *Ann Biomed Eng.* 2012;40:2355–2364. doi: 10.1007/s10439-012-0557-9
43. Fedosov DA, Dao M, Karniadakis GE, Suresh S. Computational biorheology of human blood flow in health and disease. *Ann Biomed Eng.* 2014;42:368–387. doi: 10.1007/s10439-013-0922-3
44. Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. *J Thromb Haemost.* 2016;14:906–917. doi: 10.1111/jth.13280
45. Diamond SL. Systems analysis of thrombus formation. *Circ Res.* 2016;118:1348–1362. doi: 10.1161/CIRCRESAHA.115.306824
46. Brass LF, Diamond SL, Stalker TJ. Platelets and hemostasis: a new perspective on an old subject. *Blood Adv.* 2016;1:5–9. doi: 10.1182/bloodadvances.2016000059
47. Belyaev AV, Dunster JL, Gibbins JM, Panteleev MA, Volpert V. Modeling thrombosis in silico: frontiers, challenges, unresolved problems and milestones. *Phys Life Rev.* 2018;26:27:57–95. doi: 10.1016/j.plrev.2018.02.005
48. Hemker HC, Kerdelo S, Kremers RM. Is there value in kinetic modeling of thrombin generation? No (unless...). *J Thromb Haemost.* 2012;10:1470–1477. doi: 10.1111/j.1538-7836.2012.04802.x
49. Mann KG. Is there value in kinetic modeling of thrombin generation: yes. *J Thromb Haemost.* 2012;10:1463–1469.
50. Danforth CM, Orfeo T, Mann KG, Brummel-Ziedins KE, Everse SJ. The impact of uncertainty in a blood coagulation model. *Math Med Biol.* 2009;26:323–336. doi: 10.1093/imammb/dqp011
51. Naidu PP, Anand M. Importance of VIIIa inactivation in a mathematical model for the formation, growth, and lysis of clots. *Math Model Nat Phenom.* 2014;9:17–33.
52. Méndez Rojano R, Mendez S, Lucor D, Ranc A, Giansily-Blaizot M, Schved JF, Nicoud F. Kinetics of the coagulation cascade including the contact activation system: sensitivity analysis and model reduction. *Bio-mech Model Mechanobiol.* 2019;18:1139–1153. doi: 10.1007/s10237-019-01134-4
53. Anand M, Rajagopal K, Rajagopal KR. A model for the formation, growth, and lysis of clots in quiescent plasma. A comparison between the effects of antithrombin III deficiency and protein C deficiency. *J Theor Biol.* 2008;253:725–738. doi: 10.1016/j.jtbi.2008.04.015
54. Link KG, Stobb MT, Di Paola J, Neeves KB, Fogelson AL, Sindi SS, Leiderman K. A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. *PLoS One.* 2018;13:e0200917. doi: 10.1371/journal.pone.0200917
55. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. *Am J Pathol.* 1989;134:1087–1097.
56. Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. *Thromb Res.* 1990;59:421–437. doi: 10.1016/0049-3848(90)90148-6
57. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. *Lancet.* 2003;361:1801–1809. doi: 10.1016/S0140-6736(03)13405-8
58. Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, Saisana M, Tarantola S. *Global Sensitivity Analysis: The Primer.* John Wiley & Sons; 2008.
59. Onasoga-Jarvis AA, Leiderman K, Fogelson AL, Wang M, Manco-Johnson MJ, Di Paola JA, Neeves KB. The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. *PLoS One.* 2013;8:e78732. doi: 10.1371/journal.pone.0078732
60. Shao Y, Wu W, Xu G, Wang X, Ding Q. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII. *Blood.* 2019;134:1745–1754. doi: 10.1182/blood.2018886069